BioNano Genomics, Inc. (BNGO)
| Market Cap | 1.51B |
| Revenue (ttm) | 8.50M |
| Net Income (ttm) | -41.11M |
| Shares Out | 104.25M |
| EPS (ttm) | -0.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $5.41 |
| Previous Close | $5.31 |
| Change ($) | 0.10 |
| Change (%) | 1.88% |
| Day's Open | 5.42 |
| Day's Range | 5.32 - 5.73 |
| Day's Volume | 16,195,466 |
| 52-Week Range | 0.35 - 15.69 |
The science underlining BNGO stock is incredibly compelling. But that's not what the market actually cares about right now.
It's hard to reconcile the sell-off in BNGO stock with Bionano's progress in advancing the Saphyr system - but this presents an opportunity. The post Bionano Genomics Has Disappointed, but Its NHS Deal ...
Bionano Genomics, Inc. (BNGO) closed the most recent trading day at $6.97, moving -1.13% from the previous trading session.
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) ...
The bulls are on parade.
BioNano Genomics Inc (NASDAQ:BNGO) shares are trading higher by 19.5% at $7.36 Monday on continued strength following last week's publication of DNA replication data, a fundamental process of cell growt...
Bionano's deal with the UK leaves the company well-positioned to make deals with many nations. Investors should buy BNGO stock.
Can you count on this company's novel gene diagnostic technology?
Ocugen Inc. (NASDAQ: OCGN) and Bionano Inc. (NASDAQ: BNGO) are two biopharma stocks moving higher Wednesday. Ocugen is moving after its partner Bharat Biotech announced positive study results, and Biona...
Bionano Genomics, Inc. (NASDAQ: BNGO) and Ocugen, Inc. (NASDAQ: OCGN) were among the early movers among biopharma stocks. Bionano Gains On Adoption of Genomic Mapping System By U.K. Labs: Bionano said i...
This stock market mover's growth story is just beginning.
No news; just run-of-the-mill volatility.
BNGO stock has seen too much action without fundamental justification. It makes a better speculative bet than an investment.
BNGO stock is a play on a potentially disruptive technology. But investors can't forget that most potentially disruptive technologies fail.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that multiple studies on the detection of structural variants using Bionano's optical genome mapping, ...
Is (BNGO) Outperforming Other Medical Stocks This Year?
Massive dilution, sluggish sales, and ballooning expenses will keep most away from BNGO stock despite its positive attributes. The post Bionano Will Eventually Return to Earth Due to Its Weak Fundamenta...
BNGO stock has been beaten down as of late, but it presents a great buying opportunity to invest in the emerging life sciences player. The post The Recent Pullback in Bionano Genomics Is a Major Buying ...
It may have the goods longer term, but a profitable position in BNGO stock in 2021 is tied to the price chart and maybe Ark Invest. The post This Is When Bionano Genomics Becomes a Buy appeared first on...
These stocks have been unstoppable since late December -- but will they stay that way?
Gene science will continue to drive the healthcare sector to new heights.
Bionano Genomics (BNGO) stock is on the rise Wednesday as investors react to news announced by the company after markets closed on Tuesday. The post BNGO Stock: 9 Reasons Why Bionano Genomics Shares Are...
The genomic analysis systems maker beat expectations and looks for a big jump in its installed base this year.
Shares of Bionano Genomics (NASDAQ:BNGO) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 82.61% year over year to ($0.04), which beat t...
-Solidified Financial Position Raising Approximately $335 Million in Q1 2021
Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on...
A single study launched an epic rally in BNGO stock. But the company still has much to prove, and 3,400% gains don't price in the risks.
Bionano Genomics (NASDAQ:BNGO) announces its next round of earnings this Tuesday, March 23. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.
BioNano may cause great disruption in the field of genetics. However, the payoff for investing in BNGO stock is likely to be years away.
Investors in BNGO stock have seen year-over-year stock price appreciation of more than 2,200%, but can it continue long-term? The post Valuation Not Meme Stock Status Should Worry You About Bionano Geno...
While it doesn't get a lot of press, the Autism market is unfortunately a rapidly growing market opportunity. According to recent data from the CDC, roughly 2% of all kids are now diagnosed with Autism ...
Those investors bullish on genomics might want to analyze the Q4 results of BNGO stock The post BioNano Genomics Will Likely Be Volatile Prior to Q4 Earnings appeared first on InvestorPlace. More From I...
Technically, BNGO stock appeared on the verge of a robust breakout move but with shares tumbling instead, it's time to reassess the overall picture. The post BioNano Genomics Is an Excellent Lesson in T...
SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the following investor conferences:
In the latest trading session, Bionano Genomics, Inc. (BNGO) closed at $9.38, marking a -1.57% move from the previous day.
Bionano's Saphyr system looks poised to revolutionize diagnostics and medical research, making BNGO stock worth buying for long-term investors. The post Addressable Market Aside, Bionano Stock Is a Buy ...
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management presented virtually at the H.C. Wainwright Global Life Sciences Conference, wh...
Bionano Genomics has a massive valuation based on recent capital raises. BNGO stock is fully valued at 108 times forward 2021 sales, even though sales may spike going forward.
SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 23rd, 2021 at 4:30 p.m. Eastern...
Investors need to pay close attention to Bionano Genomics (BNGO) stock based on the movements in the options market lately.
Bionano Genomics (BNGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BNGO stock is on the high side right now, especially since it will likely take time for the company's system to get traction. The post Lofty Expectations Are Already Priced Into Bionano Genomics appeare...
SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Praxis Genomics, LLC received DEX Z-codes from Palmetto MolDX for its entire testing menu of labo...
BNGO stock shot up massively in the past few months. Now isn't the time to invest as the company must first prove its technology sells.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the Cowen 41st Annual Health Care Conference. Erik H...
Bionano Genomics, Inc. (BNGO) closed at $9.84 in the latest trading session, marking a +1.13% move from the prior day.
Without revenue growth, it's hard to be bullish on BNGO stock for the long-term The post It's Time to Take Profits on Volatile BioNano Genomics Stock and Buy It Back on Dips appeared first on InvestorPl...
SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the 2021 Advances in Genome Biology and Technology (AGBT) meeting will feature presentations from...
Article published in Science reveals that optical genome mapping uniquely makes thousands of large structural variant calls Article published in Science reveals that optical genome mapping uniquely make...
About BNGO
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers ... [Read more...]
| Industry Diagnostics & Research | IPO Date Aug 21, 2018 |
| CEO R. Erik Holmlin | Employees 147 |
| Stock Exchange NASDAQ | Ticker Symbol BNGO |
Financial Performance
In 2020, BNGO's revenue was $8.50 million, a decrease of -16.06% compared to the previous year's $10.13 million. Losses were -$41.11 million, 37.9% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is 13.92, which is an increase of 157.30% from the latest price.